June 12, 2020
Takeda Pharmaceutical said on June 11 that it will divest 18 select non-core OTC and prescription drugs sold exclusively in Asia Pacific to South Korea’s Celltrion for US$278 million, in the latest deal aimed at whittling down its debt load...read more